概要
目的
明确急性淋巴细胞白血病 (ALL) 患者化疗期间继发糖尿病的发生率, 探索发生继发糖尿病的危险因素及其对患者预后的影响.
创新点
继发糖尿病在 ALL 患者化疗期间常有发生, 但其在不同化疗阶段的发生率、 危险因素及其对患者预后的影响鲜有研究. 本研究以此为切入点, 探索了 ALL 患者化疗继发糖尿病的特点及其对患者预后的影响.
方法
收集浙江大学医学院附属第一医院血液科 2011年 1 月至 2013 年 10 月期间收治的初发 ALL 病例共计 177 例, 筛选出临床资料完整且入院时不合并糖尿病的患者 156 例. 统计患者在诱导化疗期间和全化疗期间继发糖尿病的发生率, 分析糖尿病组与非糖尿病组患者在总生存期、 无事件生存期等方面的差异, 并探讨继发糖尿病的危险因素.
结论
继发糖尿病是 ALL 患者化疗期间重要的并发症, 年龄是化疗期间继发糖尿病的独立预测因子. 对于年龄小于 35 岁的年轻患者, 继发糖尿病患者 相比于正常血糖者其总生存期和无事件生存期 均缩短.
References
Alves C, Chaves C, Souza M, 2007. Transient diabetes mellitus related to l-asparaginase therapy. Arq Bras Endocrinol Metabol, 51(4):635–638. https://doi.org/10.1590/S0004-27302007000400020
American Diabetes Association, 2018. Updates to the Standards of Medical Care in Diabetes—2018. Diabetes Care, 41(9):2045–2047. https://doi.org/10.2337/dc18-su09
Banihashem A, Ghasemi A, Ghaemi N, et al., 2014. Prevalence of transient hyperglycemia and diabetes mellitus in pediatric patients with acute leukemia. Iran J Ped Hematol Oncol, 4(1):5–10.
Biondani G, Peyron JF, 2018. Metformin, an anti-diabetic drug to target leukemia. Front Endocrinol, 9:446. https://doi.org/10.3389/fendo.2018.00446
Chen WL, Wang JH, Zhao AH, et al., 2014. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood, 124(10):1645–1654. https://doi.org/10.1182/blood-2014-02-554204
Chua LL, Rajasuriar R, Lim YAL, et al., 2020. Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy. BMC Cancer, 20:151. https://doi.org/10.1186/s12885-020-6654-5
Gifford G, Milliken S, Greenfield J, 2013. Diabetic ketoacidosis secondary to l-asparaginase in acute lymphoblastic leukaemia. Intern Med J, 43(8):946–948. https://doi.org/10.1111/imj.12216
Giovannucci E, Harlan DM, ’Archer MC, et al., 2010. Diabetes and cancer: a consensus report. CA Cancer J Clin, 60(4):207–221. https://doi.org/10.3322/caac.20078
Hsu YJ, Chen YC, Ho CL, et al., 2002. Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of l-asparaginase-induced pancreatitis. Chin Med J (Taipei), 65(9):441–445.
Kantarjian HM, O’Brien S, Smith TL, et al., 2000. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol, 18(3):547. https://doi.org/10.1200/JCO.2000.18.3.547
Koltin D, Sung L, Naqvi A, et al., 2012. Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. Support Care Cancer, 20(9):2009–2015. https://doi.org/10.1007/s00520-011-1307-5
Mohn A, di Marzio A, Capanna R, et al., 2004. Persistence of impaired pancreatic β-cell function in children treated for acute lymphoblastic leukaemia. Lancet, 363(9403):127–128. https://doi.org/10.1016/S0140-6736(03)15264-6
Ouyang J, Lin J, Isnard S, et al., 2020a. The bacterium Akkermansia muciniphila: a sentinel for gut permeability and its relevance to HIV-related inflammation. Front Immunol, 11:645. https://doi.org/10.3389/fimmu.2020.00645
Ouyang J, Isnard S, Lin J, et al., 2020b. Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Ther, 17:10. https://doi.org/10.1186/s12981-020-00267-2
Rosilio C, Lounnas N, Nebout M, et al., 2013. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett, 336(1):114–126. https://doi.org/10.1016/j.canlet.2013.04.015
Thomas R, Wong WSW, Saadon R, et al., 2020. Gut microbial composition difference between pediatric ALL survivors and siblings. Pediatr Hematol Oncol, in press. https://doi.org/10.1080/08880018.2020.1759740
Wang JH, Chen WL, Li JM, et al., 2013. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci USA, 110(42):17017–17022. https://doi.org/10.1073/pnas.1315558110
Weiser MA, Cabanillas ME, Konopleva M, et al., 2004. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer, 100(6):1179–1185. https://doi.org/10.1002/cncr.20071
Zi FM, He JS, Li Y, et al., 2015. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett, 356(2):443–453. https://doi.org/10.1016/jxanlet.2014.09.050
Acknowledgments
The authors wish to thank all the medical and nursing staff working in the Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China) for providing outstanding clinical care to our patients.
Author information
Authors and Affiliations
Contributions
Jie JIN contributed to the conception and design of the study and provided administrative support. Shan-shan SUO, Chen-ying LI, Yi ZHANG, and Wen-juan YU participated in the collection and assembly of data. Shan-shan SUO and Yin-jun LOU performed data analysis and interpretation. Shan-shan SUO and Jing-han WANG were involved in the writing of the manuscript. All authors gave final approval of the manuscript for publication, and have full access to all the data in the study and take responsibility for the integrity and security of the data.
Corresponding author
Additional information
Compliance with ethics guidelines
Shan-shan SUO, Chen-ying LI, Yi ZHANG, Jing-han WANG, Yin-jun LOU, Wen-juan YU, and Jie JIN declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine (Reference Number 2013-277).
Project supported by the Zhejiang Provincial Natural Science Foundation of China (No. LY19H080009)
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Suo, Ss., Li, Cy., Zhang, Y. et al. Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients. J. Zhejiang Univ. Sci. B 21, 740–744 (2020). https://doi.org/10.1631/jzus.B1900719
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B1900719